CRISPR Screens Reveal Epstein-Barr Virus-activated JunB as a Key Lymphoblastoid B cell Dependency Factor that Represses Cyclin Dependent Kinase Inhibitor P18INK4c

This study identifies EBV-activated JunB as a critical dependency factor in lymphoblastoid B cells that drives proliferation by repressing the cell cycle inhibitor p18INK4c via an LMP1-NF-κB signaling axis, highlighting JunB as a promising therapeutic target for EBV-associated lymphoproliferative disorders.

The Gist

Imagine your body is a bustling city, and your immune system is the police force, constantly patrolling to keep things safe. Now, imagine a tiny, invisible saboteur called the Epstein-Barr Virus (EBV). It's like a master thief that has managed to sneak into over 95% of adults' cities and is hiding in the police station itself (your B-cells).

Usually, the thief is quiet, just sleeping in the back room. But sometimes, it wakes up and starts turning the police officers into a rogue, unstoppable gang. This is how EBV causes certain cancers, like lymphomas.

For a long time, scientists knew the thief (EBV) was bad, but they didn't know exactly which tools the thief used to keep the gang running. They needed to find the "secret keys" that the gang relied on to survive.

The Great Detective Hunt (CRISPR Screens)

The researchers in this paper acted like detectives using a high-tech "delete button" called CRISPR. They went through the entire instruction manual of the human cell (the genome) and systematically deleted one page at a time to see what happened.

• The Experiment: They compared two types of cells:
  1. The "Rogue Gang" (Lymphoblastoid cells): These are cells fully infected by EBV, acting wild and growing uncontrollably.
  2. The "Sleeping Gang" (Burkitt cells): These are also infected but are in a quieter, more dormant state.

They wanted to see: "If we delete this specific gene, does the Rogue Gang die, or does it keep running?"

The Big Discovery: JunB is the Gang's "Fuel Pump"

They found a specific gene called JunB. Here's the analogy:

• JunB is like the fuel pump for the Rogue Gang's car.
• When the researchers turned off the fuel pump (deleted JunB) in the Rogue Gang, the car sputtered and stopped. The cells couldn't grow anymore.
• However, when they turned off the fuel pump in the Sleeping Gang, nothing happened. The car was already parked and didn't need fuel.

This means JunB is a critical dependency only for the aggressive, cancer-causing version of the virus. It's a perfect target because if you block it, you stop the cancer without hurting the quiet, sleeping cells.

How the Thief Hacks the System (LMP1 and the Switch)

How does the virus get JunB to work? The virus has a protein called LMP1. Think of LMP1 as a remote control the thief uses to hack the cell's wiring.

1. The Remote Control: LMP1 presses a specific button (called the "TES1" switch) on the cell's control panel.
2. The Signal: This button sends a signal down a wire (a pathway called NF-κB) that tells the cell: "Make more JunB!"
3. The Result: The cell starts pumping out JunB, which keeps the cancer cells growing.

The Sabotage: Stopping the "Brakes"

So, what does JunB actually do to keep the cells growing?

Imagine the cell has a built-in emergency brake called p18INK4c. This brake is designed to stop the cell from dividing too fast. It's a safety feature to prevent cancer.

• The Villain's Move: The virus-activated JunB acts like a brake cutter. It goes to the brake pedal (p18INK4c) and cuts the wires, effectively disabling the safety mechanism.
• The Consequence: With the brakes cut, the cell spins its wheels and races out of control, dividing rapidly to form a tumor.

When the researchers deleted JunB, the "brake cutter" was gone. The emergency brake (p18INK4c) was reconnected, and the cancer cells finally stopped racing.

Why This Matters

This discovery is huge for two reasons:

1. It explains the mechanism: We now know the exact chain of events: Virus (LMP1) → Signal (NF-κB) → Fuel Pump (JunB) → Brake Cutter → Cancer Growth.
2. It offers a new treatment strategy: Since JunB is only essential for the aggressive cancer cells, drugs that block JunB (or the signal that turns it on) could be a "smart bomb." They could stop the cancer from growing without hurting healthy cells or the quiet, sleeping virus.

In a nutshell: The virus hijacks a specific switch to turn on a "fuel pump" (JunB) that cuts the "emergency brakes" (p18INK4c) of the cell. By finding this specific fuel pump, scientists have found a new way to potentially stop the cancer engine in its tracks.

Technical Summary

1. Problem Statement

Epstein-Barr virus (EBV) infects over 95% of the global adult population and is the etiological agent for various malignancies, including Burkitt lymphoma, Hodgkin lymphoma, post-transplant lymphoproliferative disease (PTLD), and nasopharyngeal carcinoma. While the viral latency programs (Latency I, II, and III) are well-characterized, effective targeted therapies for EBV-associated cancers remain limited. Specifically, the host dependency factors that drive the proliferation of EBV-transformed B-cells (Lymphoblastoid Cell Lines, or LCLs) under the fully transforming Latency III program are not fully understood. There is a critical need to identify host factors essential for LCL growth that are distinct from those required by Burkitt lymphoma cells (which typically express restricted latency programs), to uncover novel therapeutic vulnerabilities.

2. Methodology

The authors employed a comparative genome-wide CRISPR-Cas9 loss-of-function screening approach to identify host dependencies specific to EBV-transformed LCLs versus Burkitt lymphoma cells.

• Cell Models:
  • GM12878: An EBV+ LCL expressing the full Latency III program (all six EBNAs, LMP1, LMP2A).
  • P3HR-1: An EBV+ Burkitt lymphoma cell line with a genomic deletion of EBNA2, resulting in a restricted Wp-restricted latency program (primarily EBNA1 and BHRF1).
  • Additional validation was performed using other LCLs (GM13111, GM15892) and Burkitt lines (Mutu I, Mutu III, Jijoye, Daudi).
• Screening Strategy:
  • Cells were transduced with the Brunello sgRNA library (77,441 guides targeting human genes) at a low multiplicity of infection (MOI ~0.3) to ensure single integration.
  • Cells were passaged for 21 days under puromycin selection.
  • sgRNA abundance was quantified via next-generation sequencing (NGS) at Day 21 compared to input.
  • Hits were identified using the STARS algorithm (q < 0.05), comparing depletion in GM12878 vs. P3HR-1.
• Downstream Validation & Mechanism:
  • CRISPR Knockout (KO): Validation of hits (specifically JunB) using independent sgRNAs.
  • Phenotypic Assays: Cell proliferation (CellTiter-Glo, CFSE dilution), apoptosis (7-AAD uptake), and cell cycle analysis (PI staining).
  • Molecular Mechanisms:
    • LMP1 Signaling: Conditional LMP1 expression in EBV-negative Burkitt cells (Daudi, BL41, Akata) and LMP1 KO in LCLs to test JunB regulation.
    • Mutagenesis: Testing LMP1 Transformation Effector Sites (TES1/CTAR1 and TES2/CTAR2) mutants to map signaling pathways.
    • Transcriptomics: RNA-seq of JunB-KO LCLs to identify differentially expressed genes.
    • ChIP-seq Integration: Cross-referencing RNA-seq data with ENCODE JunB ChIP-seq data and EBNA3A/C ChIP-seq data to map direct vs. indirect targets.
    • Genetic Rescue: Using CRISPR activation (CRISPRa) to overexpress CDKN2C (p18INK4c) and double-KO experiments (JunB + CDKN2C) to test epistasis.

3. Key Contributions

• Identification of JunB as an LCL-Specific Dependency: The study establishes JunB (an AP-1 transcription factor) as a critical host dependency factor specifically required for the proliferation of Latency III LCLs, but dispensable for Latency I Burkitt lymphoma cells.
• Elucidation of the LMP1-JunB Axis: The authors demonstrate that LMP1 is the upstream driver of JunB expression in LCLs, specifically via the TES1/CTAR1 domain and the canonical NF-κB signaling pathway.
• Mechanism of Cell Cycle Regulation: The paper defines a novel mechanism where EBV-activated JunB represses the cell cycle inhibitor p18INK4c (encoded by CDKN2C), thereby allowing G1/S progression.
• Integration of Viral and Host Repressors: The study reveals a cooperative repression mechanism where JunB, in complex with host factors BATF and IRF4, recruits viral EBNA3A/3C proteins to the CDKN2C promoter to silence its expression.

4. Key Results

• Screening Outcomes: The Brunello screen identified 158 LCL-selective hits. JunB emerged as a top hit, with three of four sgRNAs significantly depleted in GM12878 but not in P3HR-1. This was validated across multiple LCL/Burkitt pairs.
• Phenotypic Characterization:
  • JunB KO in LCLs caused a significant reduction in proliferation and an accumulation of cells in the G0/G1 and S phases, with a corresponding decrease in G2/M progression.
  • Crucially, JunB depletion did not induce significant apoptosis (no increase in BIM or 7-AAD uptake), distinguishing its role from other LCL dependencies like BATF/IRF4.
• LMP1 Dependence:
  • JunB protein levels were markedly higher in Latency III cells (LCLs, Jijoye) compared to Latency I cells (P3HR-1, Mutu I).
  • Acute LMP1 KO in LCLs rapidly depleted JunB protein.
  • Conditional LMP1 expression induced JunB in EBV-negative cells. This induction was abolished by IKKβ inhibition (blocking NF-κB) and by mutating the LMP1 TES1 domain, confirming the TES1-NF-κB axis is required for JunB upregulation.
• Transcriptional Regulation of CDKN2C:
  • RNA-seq of JunB-KO LCLs revealed CDKN2C (p18INK4c) as the most significantly upregulated transcript.
  • ChIP-seq analysis showed that JunB, BATF, and IRF4 co-occupy a site near the CDKN2C promoter, which is also bound by EBNA3A and EBNA3C.
  • Epigenetic marks at the CDKN2C locus in LCLs suggest a poised state for repression by this complex.
• Genetic Rescue:
  • Overexpression of p18INK4c strongly inhibited LCL proliferation but had a minimal effect on Burkitt cells.
  • Double Knockout: Simultaneous deletion of JunB and CDKN2C in LCLs partially rescued the growth defect caused by JunB KO alone. This confirms that JunB promotes LCL proliferation primarily by repressing p18INK4c.

5. Significance

• Therapeutic Targeting: The study identifies JunB and the LMP1-JunB-p18INK4c axis as potential therapeutic targets for EBV-associated lymphoproliferative disorders (e.g., PTLD). Since LMP1 itself is difficult to target directly, downstream host factors like JunB offer a druggable avenue.
• Mechanistic Insight: The findings clarify how EBV Latency III reprograms the host cell cycle. It highlights a non-redundant mechanism where the virus utilizes a specific host transcription factor (JunB) to silence a specific tumor suppressor (p18INK4c) to drive proliferation, distinct from the c-MYC driven metabolism seen in Burkitt lymphoma.
• Cross-Talk Discovery: The paper provides evidence of complex cross-talk between viral oncoproteins (LMP1, EBNA3A/C) and host transcription factors (JunB, BATF, IRF4) to epigenetically silence cell cycle inhibitors.
• Clinical Relevance: Given that CDK6 (the target of p18INK4c) is an LCL dependency factor and CDK6 inhibitors (e.g., palbociclib) are FDA-approved, the study suggests that combining CDK6 inhibitors with agents targeting the JunB pathway or EZH2 (which aids in p18INK4c repression) could be a synergistic strategy for treating EBV-driven malignancies.